The SFI Group is committed to providing clinically proven natural health solutions to healthcare professionals and consumers worldwide
Soho Flordis International (SFI), through its Swiss subsidiary company Ginsana SA, will acquire leading UK manufacturer and supplier of traditional herbal treatments Potter's, from Vifor Pharma, a company of the Galenica Group.
Potter's, based in Wigan, England, has more than 200 years of history as a producer of high quality herbal-based treatments and is the oldest herbal medicine company in the United Kingdom. Its extensive range of well-established products includes treatments for coughs and colds, pain and joint care, gastro-intestinal disorders and women’s health. In addition to this range of products, Potter's features brands like Red Kooga®, Seatone®, Calcia™ as well as Equazen™, one of the world’s leading fish oil containing health products.
The Equazen™ brand is backed by robust specific clinical research and in recent years has expanded to deliver brain health solutions to various patient groups. The brand also includes the international product Equazen™ eye-q®. Potter's products are sold throughout the UK by leading retailers such as Boots and Holland & Barrett as well as pharmacy and health food outlets.
With subsidiary companies in Europe, Asia and America, the SFI Group draws on more than 70 years of international experience in the high-quality natural health sector. The SFI Group is committed to providing clinically proven natural health solutions to health professionals and consumers worldwide.
Vifor Pharma is a global leader in the treatment of iron deficiency. Vifor Pharma has decided to focus its resources and efforts on maximising and expanding its portfolio of specialty pharmaceuticals as it prepares for life as a stand-alone company.
Nigel Pollard, CEO of SFI, commented: “Potter's is a strong and iconic brand in the natural medicine sector. Together with its history of over two centuries, Potter's will bring to the SFI Group an excellent team and an extensive portfolio of trusted products. These products and the business platform in the UK and Europe are an excellent fit for SFI as we seek to build our world leading position in the field of clinically-proven natural medicine.”
The transaction is expected to be completed in the fourth quarter of 2015. Financial details of the transaction were not disclosed.
Equazen™ eye-q® is a dietary supplement with a specific combination of omega-3 and omega-6 fatty acids from natural sources (fish oil and evening primrose oil). Equazen™ eye-q® unique formulation has been tested in clinical trials and showed efficacy in brain function, particularly in children and adolescents with learning disabilities, cognitive & developmental disorders.
References upon request.